Hypertriglyceridemia

NuraLogix researchers announce AI models that can predict Metabolic Risks

Retrieved on: 
수요일, 8월 10, 2022
Machine learning, Cardiovascular disease, Hypertension, Health, Metabolic syndrome, Technology, Transdermal optical imaging, Smartphone, TOI, Association of British HealthTech Industries, Type 2 diabetes, Globe, NCD, AUC, Research, Health Resources and Services Administration, Population health, Anura, Medical device, Hypercholesterolemia, Hypertriglyceridemia

TORONTO, Aug. 10, 2022 /PRNewswire/ -- Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed AI models that can predict a person's risk ofType 2 Diabetes, Hypercholesterolemia, Hypertriglyceridemia and Hypertension.

Key Points: 
  • TORONTO, Aug. 10, 2022 /PRNewswire/ -- Researchers at NuraLogix, a global leader in HealthTech AI, announced today that they have developed AI models that can predict a person's risk ofType 2 Diabetes, Hypercholesterolemia, Hypertriglyceridemia and Hypertension.
  • Researchers at the company trained their machine learning based models on the facial blood flow patterns of tens of thousands of subjects who had been diagnosed with the above conditions.
  • All of the models predicted with a minimum AUC > 0.80.
  • Compare this with the classic Framingham model for predicting cardiovascular disease which had an AUC in the range of 0.70.

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Retrieved on: 
화요일, 8월 9, 2022
FDA, Intellectual property, U.S. Securities and Exchange Commission, Cardiovascular disease, CCR2, Chronic kidney disease, CD36, Nasdaq, Hepatocyte, Risk, Tokyo Stock Exchange, Gene, Inflammation, Arachidonic acid, International Diabetes Federation, Metabolic syndrome, MS, IPF, GLOBE, Failure, Hypercholesterolemia, Private Securities Litigation Reform Act, IDF, Non-alcoholic fatty liver disease, MCP-1, Code, T2DM, Incidence, Amyotrophic lateral sclerosis, Prevalence, Congress, Security (finance), Research, LOXL2, Hypertriglyceridemia, Form 8-K, Patient, Fibrosis, Type 2 diabetes, NAFLD, PDE, Form 10-K, DCM, Neurodegeneration, NASDAQ, Idiopathic pulmonary fibrosis, Glioblastoma, Dyslipidemia, ABCG1, MD, Annual report, ALS, Multiple sclerosis, RNA transfection, Malignancy, Pharmaceutical industry

This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.

Key Points: 
  • This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA.
  • NAFLD is considered the hepatic manifestation of metabolic syndrome; studies have reported that 50% of patients with metabolic syndrome also have NAFLD.
  • The presence of dyslipidemia (hypercholesterolemia, hypertriglyceridemia, or both) is reported in 20 - 80% of NAFLD cases.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

Eccogene Announces US IND Approval for THRβ agonist ECC4703

Retrieved on: 
월요일, 8월 1, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hypertriglyceridemia, Population, Food, Trial of the century, THR, Hypercholesterolemia, CEO, Liver, NASH, Safety, LDL, Metabolic syndrome, FDA, Pharmacokinetics, Obesity, Prevalence, IND, Pharmaceutical industry, Dyslipidemia

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S.

Key Points: 
  • SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S.
  • This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants and subjects with elevated LDL.
  • Thyroid hormone receptor (THR) isa type of nuclear receptor that is activated by thyroid hormone.
  • THR in the liver is responsible for the benefits of liver fat reduction and atherogenic lipid lowering.

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

Retrieved on: 
화요일, 7월 26, 2022
Proton, Patient, Male, IPF, Dyslipidemia, Multiple sclerosis, GLOBE, LOXL2, PDE, Malignancy, Hypertriglyceridemia, Glioblastoma, U.S. Securities and Exchange Commission, Amyotrophic lateral sclerosis, Female, Doctor of Philosophy, T2DM, Hypercholesterolemia, Neurodegeneration, Code, Cardiovascular disease, Intellectual property, Form 8-K, Incidence, Private Securities Litigation Reform Act, NAFLD, NDA, Chronic kidney disease, Fibrosis, Risk, Failure, Safety, Arachidonic acid, DCM, Gene, MCP-1, Fasting, Inflammation, MS, Metabolic syndrome, ALS, FDA, MD, Security (finance), Tokyo Stock Exchange, Nasdaq, Annual report, Week, Hepatocyte, Idiopathic pulmonary fibrosis, Non-alcoholic fatty liver disease, Form 10-K, CCR2, Prevalence, Element, Pharmaceutical industry

Kazuko Matsuda, MD, PhD, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased that this Phase 2 trial evaluating MN-001 has commenced.

Key Points: 
  • Kazuko Matsuda, MD, PhD, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased that this Phase 2 trial evaluating MN-001 has commenced.
  • MN-001 appears to reduce serum lipid profiles in patients with a dual diagnosis of NAFLD and T2DM/prediabetes with dyslipidemia.
  • This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MN-001 (tipelukast) in patients with NAFLD, T2DM and hypertriglyceridemia.
  • The design of the Phase 2 clinical trial includes the following elements:
    Approximately 40 male and female patients, ages 21 to 75 years, in the U.S.

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Retrieved on: 
화요일, 7월 5, 2022
Janus, 808, 4th floor, NASH, Liver, Attention, FGF21, GLOBE, RBC Capital Markets, Sale, Capital market, U.S. Securities and Exchange Commission, Prospectus, Telephone, Hypertriglyceridemia, Fatty liver disease, State Street, Park Avenue, Cantor Fitzgerald, SAN, SVB, Vesey Street, BofA Securities, SEC, Syndicate, RA, Security (finance), Equity capital markets, 3rd Floor, Cantor

The pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately.

Key Points: 
  • The pre-funded warrants have an exercise price of $0.001 per share, and are exercisable immediately.
  • The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance.
  • The offering was anchored by leading healthcare and life sciences investors including BVF Partners L.P., Deep Track Capital, RA Capital Management, Braidwell LP, Janus Henderson Investors and other institutional investors.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 89bio, were approximately $94.5 million.

Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Retrieved on: 
금요일, 7월 1, 2022
Health, General Health, Review, III, ROA, Report, Research, Epidemiology, Population, Disease, Hypertriglyceridemia, Prevalence, United Kingdom, CAGR, MOA, SWOT, Pharmaceutical industry, Lithium, Dietary supplement, Medical device

The "Severe Hypertriglyceridemia (SHTG) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Severe Hypertriglyceridemia (SHTG) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Severe Hypertriglyceridemia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Severe Hypertriglyceridemia market size from 2019 to 2032.
  • The Report also covers current Severe Hypertriglyceridemia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Retrieved on: 
수요일, 6월 29, 2022
808, 4th floor, NASH, Liver, Attention, FGF21, GLOBE, RBC Capital Markets, Exercise, Capital market, Sale, U.S. Securities and Exchange Commission, Prospectus, Telephone, Hypertriglyceridemia, Fatty liver disease, State Street, Park Avenue, Cantor Fitzgerald, SAN, Disclosure, Risk, The O.C., Private Securities Litigation Reform Act, SVB, Health, Vesey Street, BofA Securities, SEC, Syndicate, Safe harbor, Security (finance), Equity capital markets, 3rd Floor, Cantor

The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance.

Key Points: 
  • The warrants have an exercise price of $5.325 per share, are exercisable immediately, and will expire two years following the date of issuance.
  • The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $94.5 million.
  • The offering is expected to close on or about July 1, 2022, subject to the satisfaction of customary closing conditions.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Retrieved on: 
화요일, 6월 28, 2022
808, NASH, Liver, Attention, FGF21, GLOBE, Exercise, Sale, U.S. Securities and Exchange Commission, Prospectus, Telephone, Hypertriglyceridemia, Fatty liver disease, State Street, SAN, Disclosure, Risk, The O.C., Private Securities Litigation Reform Act, SVB, Health, BofA Securities, SEC, Safe harbor, Security (finance), 3rd Floor

The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Key Points: 
  • The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • All of the securities to be sold in the offering are being offered by 89bio.
  • BofA Securities and SVB Securities are acting as book-running managers for the offering.
  • The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

Retrieved on: 
화요일, 6월 28, 2022
NASH, Patient, LinkedIn, Liver, Trial of the century, FGF21, Diabetes, Population, Hypertriglyceridemia, Fatty liver disease, Inflammation, Steatosis, Disclosure, The O.C., Investor, Event, TGS, Private Securities Litigation Reform Act, Half-life, Histology, Cardiovascular disease, Glycated hemoglobin, Fibrosis, SEC, PST, Diarrhea, Webcast, Safety, Physician, EST, Safe harbor, Nausea, Medical imaging, Pharmaceutical industry

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), today announced positive topline results from ENTRIGUE, the Phase 2 proof-of-concept study evaluating pegozafermin for the treatment of severe hypertriglyceridemia (SHTG). Treatment with pegozafermin resulted in clinically meaningful and significant reductions in triglycerides (TG) from baseline across all doses (with a 63% reduction in the highest dosing group; p

Key Points: 
  • Results also demonstrated a significant reduction in liver enzymes and an improvement in glycemic control markers in pegozafermin treated patients.
  • Pegozafermin continues to be generally well tolerated with a favorable safety profile across doses consistent with prior studies.
  • These results also build confidence in our ongoing Phase 2b ENLIVEN trial in NASH with data expected in the first quarter of 2023.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

Retrieved on: 
목요일, 6월 23, 2022
Multiple sclerosis, Nasdaq, Fibrosis, CCR2, Code, Intellectual property, Department, Security (finance), FDA, Substance dependence, Inflammation, Non-alcoholic fatty liver disease, Lipid metabolism, Amyotrophic lateral sclerosis, Gene, Juntendo University, School, Medical laboratory, NAFLD, Arachidonic acid, Medical school, U.S. Securities and Exchange Commission, Tokyo Stock Exchange, Dyslipidemia, Private Securities Litigation Reform Act, Form 8-K, Metabolic syndrome, Neurodegeneration, Annual report, LDL, MD, Hypertriglyceridemia, Failure, PDE, LOXL2, MS, Hepatocyte, IPF, Patient, DCM, Idiopathic pulmonary fibrosis, MPH, MCP-1, Form 10-K, ALS, GLOBE, Glioblastoma, Risk, Pharmaceutical industry

It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.

Key Points: 
  • It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously.
  • Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.